47.69
0.57 (1.21%)
| Penutupan Terdahulu | 47.12 |
| Buka | 48.17 |
| Jumlah Dagangan | 316,781 |
| Purata Dagangan (3B) | 543,659 |
| Modal Pasaran | 1,766,316,032 |
| Harga / Pendapatan (P/E Ke hadapan) | 68.49 |
| Harga / Jualan (P/S) | 4.99 |
| Harga / Buku (P/B) | 26.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Mar 2026 |
| Margin Keuntungan | -10.19% |
| Margin Operasi (TTM) | -23.48% |
| EPS Cair (TTM) | -0.610 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 38.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 410.02% |
| Nisbah Semasa (MRQ) | 0.910 |
| Aliran Tunai Operasi (OCF TTM) | 2.09 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -26.88 M |
| Pulangan Atas Aset (ROA TTM) | 0.90% |
| Pulangan Atas Ekuiti (ROE TTM) | -37.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Harrow, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -5.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.60 |
|
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company’s FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company’s ophthalmology-focused pharmaceutical compounding business. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 15.07% |
| % Dimiliki oleh Institusi | 57.11% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 91.00 (Cantor Fitzgerald, 90.82%) | Beli |
| Median | 80.50 (68.80%) | |
| Rendah | 70.00 (HC Wainwright & Co., 46.78%) | Beli |
| Purata | 80.50 (68.80%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 39.22 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 04 Mar 2026 | 91.00 (90.82%) | Beli | 39.22 |
| HC Wainwright & Co. | 04 Mar 2026 | 70.00 (46.78%) | Beli | 39.22 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | - | 38.92 | -198,572 | -7,751,205 |
| Jumlah Keseluruhan Kuantiti Bersih | -198,572 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -7,751,205 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 38.92 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | 04 Mar 2026 | Jual (-) | 138,263 | 39.22 | 5,422,675 | |
| OPALEYE MANAGEMENT INC. | 03 Mar 2026 | Jual (-) | 60,309 | 38.61 | 2,328,530 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Feb 2026 | Pengumuman | Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |